Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio. defined as the PFS interval associated with molecularly guided therapy (PFS2) divided by the PFS interval associated with the last prior systemic therapy (PFS1). above 1. https://www.roneverhart.com/Straight-Blade-Receptacles-Duplex-2P-3W-20A-125V-5-20R-WHITE-HUBBELL-5362W/